PubRank

Ugo D'Oro

Author PubWeight™ 17.60‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Inhibition of natural killer cells through engagement of CD81 by the major hepatitis C virus envelope protein. J Exp Med 2002 2.64
2 Activation of naïve B lymphocytes via CD81, a pathogenetic mechanism for hepatitis C virus-associated B lymphocyte disorders. Proc Natl Acad Sci U S A 2005 1.76
3 Adjuvanticity of the oil-in-water emulsion MF59 is independent of Nlrp3 inflammasome but requires the adaptor protein MyD88. Proc Natl Acad Sci U S A 2011 1.44
4 Immunology of TLR-independent vaccine adjuvants. Curr Opin Immunol 2009 1.24
5 Activation of src-family tyrosine kinases by LPS regulates cytokine production in dendritic cells by controlling AP-1 formation. Eur J Immunol 2003 1.12
6 Differential IL-17 production and mannan recognition contribute to fungal pathogenicity and commensalism. J Immunol 2010 1.02
7 T cell costimulation by the hepatitis C virus envelope protein E2 binding to CD81 is mediated by Lck. Eur J Immunol 2003 0.99
8 Cyclic AMP modulates the functional plasticity of immature dendritic cells by inhibiting Src-like kinases through protein kinase A-mediated signaling. J Biol Chem 2004 0.96
9 Introduction of zwitterionic motifs into bacterial polysaccharides generates TLR2 agonists able to activate APCs. J Immunol 2007 0.91
10 A point mutation in the amino terminus of TLR7 abolishes signaling without affecting ligand binding. J Immunol 2011 0.87
11 DC-ATLAS: a systems biology resource to dissect receptor specific signal transduction in dendritic cells. Immunome Res 2010 0.87
12 Src kinases are required for a balanced production of IL-12/IL-23 in human dendritic cells activated by Toll-like receptor agonists. PLoS One 2010 0.86
13 Genetically detoxified pertussis toxin (PT-9K/129G): implications for immunization and vaccines. Expert Rev Vaccines 2014 0.83
14 Optimizing anti-CD3 affinity for effective T cell targeting against tumor cells. Eur J Immunol 2002 0.79
15 A new TLR2 agonist promotes cross-presentation by mouse and human antigen presenting cells. Hum Vaccin Immunother 2015 0.77
16 Surface molecules on stimulated plasmacytoid dendritic cells are sufficient to cross-activate resting myeloid dendritic cells. Hum Immunol 2011 0.77